Iemasa Koh1, Suguru Nosaka2, Masaki Sekine2, Jun Sugimoto2, Eiji Hirata2, Yoshiki Kudo2. 1. Department of Obstetrics and Gynecology, Faculty of Medicine Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan iemasakoh550317@gmail.com. 2. Department of Obstetrics and Gynecology, Faculty of Medicine Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Abstract
BACKGROUND/AIM: The biological importance of the caudal-related homeobox transcription factor CDX2 in acquiring resistance to anticancer drugs has been studied in ovarian mucinous carcinoma. CDX2 promotes the expression of multidrug resistance 1 (MDR1) and confers resistance to paclitaxel. The regenerating islet-derived family member 4 (REG4) gene is a potential target gene of CDX2. In this study, we investigated the relationship between the expression of CDX2 and Reg IV and the regulation of Reg IV expression and examined novel chemotherapeutic regimens. MATERIALS AND METHODS: The regulation of Reg IV expression by CDX2 and sensitivity of 5-fluorouracil (5-FU) were evaluated using ovarian mucinous cancer cell lines. RESULTS: The correlation of CDX2 with Reg IV expression was demonstrated in ovarian mucinous carcinoma. Reg IV expression was enhanced by transfection of CDX2 and was suppressed by inhibition of CDX2 expression. OMC-3 cells with ectopically overexpressed CDX2 showed enhanced apoptosis and sensitivity to 5-FU. CONCLUSION: CDX2 promotes resistance to paclitaxel and sensitivity to 5-FU. Novel 5-FU-based chemotherapy based on CDX2 may be used in ovarian mucinous carcinoma. Copyright
BACKGROUND/AIM: The biological importance of the caudal-related homeobox transcription factor CDX2 in acquiring resistance to anticancer drugs has been studied in ovarian mucinous carcinoma. CDX2 promotes the expression of multidrug resistance 1 (MDR1) and confers resistance to paclitaxel. The regenerating islet-derived family member 4 (REG4) gene is a potential target gene of CDX2. In this study, we investigated the relationship between the expression of CDX2 and Reg IV and the regulation of Reg IV expression and examined novel chemotherapeutic regimens. MATERIALS AND METHODS: The regulation of Reg IV expression by CDX2 and sensitivity of 5-fluorouracil (5-FU) were evaluated using ovarian mucinous cancer cell lines. RESULTS: The correlation of CDX2 with Reg IV expression was demonstrated in ovarian mucinous carcinoma. Reg IV expression was enhanced by transfection of CDX2 and was suppressed by inhibition of CDX2 expression. OMC-3 cells with ectopically overexpressed CDX2 showed enhanced apoptosis and sensitivity to 5-FU. CONCLUSION:CDX2 promotes resistance to paclitaxel and sensitivity to 5-FU. Novel 5-FU-based chemotherapy based on CDX2 may be used in ovarian mucinous carcinoma. Copyright
Authors: Takao Hinoi; Peter C Lucas; Rork Kuick; Samir Hanash; Kathleen R Cho; Eric R Fearon Journal: Gastroenterology Date: 2002-11 Impact factor: 22.682
Authors: Raquel Almeida; Elisabete Silva; Filipe Santos-Silva; Debra G Silberg; Jiangfu Wang; Carmen De Bolós; Leonor David Journal: J Pathol Date: 2003-01 Impact factor: 7.996
Authors: Kumar S Bishnupuri; Qizhi Luo; Nabendu Murmu; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe Journal: Gastroenterology Date: 2006-01 Impact factor: 22.682
Authors: Y Mitani; N Oue; S Matsumura; K Yoshida; T Noguchi; M Ito; S Tanaka; H Kuniyasu; N Kamata; W Yasui Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Jodi-Ann Edwards; Nicholas Tan; Nadlie Toussaint; Peiqi Ou; Cathy Mueller; Albert Stanek; Vladimir Zinsou; Sean Roudnitsky; Michelle Sagal; Lisa Dresner; Alexander Schwartzman; Chongmin Huan Journal: World J Gastroenterol Date: 2020-06-07 Impact factor: 5.742
Authors: Jared A Sninsky; Kumar S Bishnupuri; Iván González; Nikolaos A Trikalinos; Ling Chen; Brian K Dieckgraefe Journal: Oncotarget Date: 2021-02-16